Your browser doesn't support javascript.
loading
Role of HMGB1 in Cutaneous Melanoma: State of the Art.
Li Pomi, Federica; Borgia, Francesco; Custurone, Paolo; Vaccaro, Mario; Pioggia, Giovanni; Gangemi, Sebastiano.
Afiliación
  • Li Pomi F; Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.
  • Borgia F; Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.
  • Custurone P; Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.
  • Vaccaro M; Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, 98125 Messina, Italy.
  • Pioggia G; Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy.
  • Gangemi S; Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.
Int J Mol Sci ; 23(16)2022 Aug 18.
Article en En | MEDLINE | ID: mdl-36012593
ABSTRACT
High-mobility Group Box 1 (HMGB1) is a nuclear protein that plays a key role in acute and chronic inflammation. It has already been studied in several diseases, among them melanoma. Indeed, HMGB1 is closely associated with cell survival and proliferation and may be directly involved in tumor cell metastasis development thanks to its ability to promote cell migration. This research aims to assess the role of this molecule in the pathogenesis of human melanoma and its potential therapeutic role. The research has been conducted on the PubMed database, and the resulting articles are sorted by year of publication, showing an increasing interest in the last five years. The results showed that HMGB1 plays a crucial role in the pathogenesis of skin cancer, prognosis, and therapeutical response to therapy. Traditional therapies target this molecule indirectly, but future perspectives could include the development of new target therapy against HMGB1, thus adding a new approach to the therapy, which has often shown primary and secondary resistance. This could add a new therapy arm which has to be prolonged and specific for each patient.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Proteína HMGB1 / Melanoma Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Proteína HMGB1 / Melanoma Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2022 Tipo del documento: Article País de afiliación: Italia